Hepatitis C therapy: Highlights from the 2012 annual meeting of the european association for the study of the liver

Clinical Infectious Diseases

Volumn 56, Issue 4, 2013, Pages 560-566

  Graham, Camilla S ^a   Barreiro, Pablo ^a   Vispo, Eugenia ^a   Poveda, Eva ^a   Fernández Montero, Jose V ^a   Soriano, Vincent ^a  

^a HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

Author keywords

DAA; directly acting antivirals; drug resistance; hepatitis C; HIV

Indexed keywords

ABT 072; ABT 333; ABT 450; ANTIVIRUS AGENT; ASUNAPREVIR; BOCEPREVIR; DACLATASVIR; DANOPREVIR; FALDAPREVIR; GS 5885; GS 9451; INTERLEUKIN 28B; LOMIBUVIR; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; NONSTRUCTURAL PROTEIN 5A; PEGINTERFERON ALPHA2A PLUS RIBAVIRIN; PROTEINASE INHIBITOR; RITONAVIR; SIMEPREVIR; SOFOSBUVIR; TEGOBUVIR; TELAPREVIR; UNCLASSIFIED DRUG;

ANEMIA; ANTIVIRAL RESISTANCE; ARTICLE; DRUG ERUPTION; DRUG POTENCY; DRUG SAFETY; DRUG TOLERANCE; DRUG WITHDRAWAL; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; INNATE IMMUNITY; MEDICAL SOCIETY; NEUTROPENIA; NONHUMAN; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; THROMBOCYTOPENIA; UNSPECIFIED SIDE EFFECT; VIREMIA; VIRUS IMMUNITY;

ANTIVIRAL AGENTS; CLINICAL TRIALS AS TOPIC; CONGRESSES AS TOPIC; DRUG THERAPY, COMBINATION; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; IMIDAZOLES; INTERLEUKINS; PROTEASE INHIBITORS; URIDINE MONOPHOSPHATE; VIRAL LOAD; VIRAL NONSTRUCTURAL PROTEINS;

EID: 84873027142     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/cis915     Document Type: Article

References (54)

1. Alter H. Hepatitis C: the end of the beginning and possibly the beginning of the end. Ann Intern Med 2012; 156:317-9.
2. Soriano V, Poveda E, Vispo E, Labarga P, Rallón N, Barreiro P. Pharmacogenetics of hepatitis C. J Antimicrob Chemother 2012; 67:523-9.
3. Hezode C, Dorival C, Zoulim F, et al. Safety of telaprevir and boceprevir in combination with peginterferon alfa/ribavirin in cirrhotic nonresponders. First results of the French early access program (ANRS CO20-CUPIC). In: 47th EASL, Barcelona, 18-22 April 2012. Abstract 8.
4. Bronowicki J, Davis M, Flamm S, et al. Sustained virologic response (SVR) in prior peginterferon/ribavirin (PR) treatment failures after retreatment with boceprevir (BOC) + PR: the PROVIDE study interim results. In: 47th EASL, Barcelona, 18-22 April 2012. Abstract 11.
5. Mallolas J, Pol S, Rivero A, et al. Boceprevir plus peginterferon/ ribavirin for the treatment of HCV/HIV co-infected patients: end of treatment (week 48) interim results. In: 47th EASL, Barcelona, 18-22 April 2012. Abstract 50.
6. Soriano V, Sherman K, Rockstroh J, et al. Challenges and opportunities for hepatitis C drug development in HIV-hepatitis C viruscoinfected patients. AIDS 2011; 25:2197-208.
7. Goelzer P, Morcos P, Tran J, et al. Ritonavir substantially reduces reactive metabolite formation of the HCV protease inhibitor danoprevir both in vitro and in vivo. In: 47th EASL, Barcelona, 18-22 April 2012. Abstract 1180.
8. Everson G, Cooper C, Hézode C, et al. Rapid and sustained achievement of undetectable HCV RNA during treatment with ritonavirboosted danoprevir/peg-IFNa-2a/RBV in HCV genotype 1 or 4 patients: DAUPHINE week 12 interim analysis. In: 47th EASL, Barcelona, 18-22 April 2012. Abstract 1177.
9. Zeuzem S, Berg T, Gane E, et al. TMC435 in HCV genotype 1 patients who have failed previous pegylated interferon/ribavirin treatment: final SVR24 results of the ASPIRE trial. In: 47th EASL, Barcelona, 18-22 April 2012. Abstract 2.
10. Lawitz E, Poordad F, De Jesus E, et al. ABT-450/ritonavir (ABT-450/r) combined with pegylated interferon alpha-2a/ribavirin after 3-day monotherapy in genotype 1 (GT1) HCV-infected treatmentnaive subjects: 12-week sustained virologic response. In: 47th EASL, Barcelona, 18-22 April 2012. Abstract 1187.
11. Gane E, Roberts S, Stedman C, et al. Oral combination therapy with a nucleoside polymerase inhibitor (RG7128) and danoprevir for chronic hepatitis C genotype 1 infection (INFORM-1): a randomised, double-blind, placebo-controlled, dose-escalation trial. Lancet 2010; 376:1467-75.
12. Gane E, Pockros P, Zeuzem S, et al. Interferon-free treatment with a combination of mericitabine and danoprevir/r with or without ribavirin in treatment-naive HCV genotype 1-infected patients. In: 47th EASL, Barcelona, 18-22 April 2012. Abstract 1412.
13. Kowdley K, Lawitz E, Crespo I, et al. ATOMIC: 97% RVR for PSI-7977 + PEG/RBV x 12 week regimen in HCV GT1: an end to response-guided therapy? In: 47th EASL, Barcelona, 18-22 April 2012. Abstract 1.
14. Lawitz E, Gane E, Stedman C, et al. PSI-7977 PROTON and ELECTRON: 100% concordance of SVR4 with SVR24 in HCV GT1, GT2 & GT3. In: 47th EASL, Barcelona, 18-22 April 2012. Abstract 7.
15. Gane E, Stedman C, Hyland R, et al. Once daily PSI-7977 plus RBV: pegylated interferon-α not required for complete rapid viral response in treatment-naive patients with HCV GT2 or GT3. In: 62nd AASLD, San Francisco, CA, 4-8 November 2011. Abstract 34.
16. Gane E, Stedman C, Hyland R, et al. ELECTRON: once daily PSI-7977 plus RBV in HCV GT1/2/3. In: 47th EASL, Barcelona, 18-22 April 2012. Abstract 1113.
17. Gane E, Stedman C, Anderson J, et al. 100% rapid virologic response for PSI-7977 + ribavirin in genotype 1 null responders (ELECTRON): early viral decline similar to that observed in genotype 1 and genotypes 2/3 treatment-naive patients. In: 19th CROI, Seattle, WA, 5-8 March 2012. Abstract 54LB.
18. Jacobson I, Lawitz E, Lalezari J, et al. PSI-7977 400 mg QD safety and tolerability in the first 450 patients treated for 12 weeks. In: 47th EASL, Barcelona, 18-22 April 2012. Abstract 1120.
19. Lawitz E, Rodriguez-Torres M, Cornpropst M, et al. The effect of hepatic impairment on the pharmacokinetics and antiviral activity of PSI-7977 in hepatitis C infected subjects treated for seven days. In: 47th EASL, Barcelona, 18-22 April 2012. Abstract 1130.
20. Sulkowski M, Gardiner D, Lawitz E, et al. Potent viral suppression with all-oral combination of daclatasvir (NS5A inhibitor) and GS-7977 (NS5B inhibitor), +/-ribavirin, in treatment-naive patients with chronic HCV GT1, 2, or 3. In: 47th EASL, Barcelona, 18-22 April 2012. Abstract 1422.
21. Zuzem S, Soriano V, Asselah T, et al. SVR4 and SVR12 with an interferon-free regimen of BI-201335 and BI-207127 ± ribavirin in treatment-naïve patients with genotype 1 HCV infection: interim results of SOUND-C2. In: 47th EASL, Barcelona, 18-22 April 2012. Abstract 101.
22. Soriano V, Gane E, Angus P, et al. The efficacy and safety of the interferon-free combination of BI-201335 and BI-207127 in genotype 1 HCV patients with cirrhosis-interim analysis from SOUND-C2. In: 47th EASL, Barcelona, 18-22 April 2012. Abstract 1420.
23. Zhang E, Tigges A, Jiang M, et al. Characterization of HCV variants in genotype 1 treatment-naive patients administered the combination of TVR and VX-222 in DUAL arms of ZENITH study. In: 47th EASL, Barcelona, 18-22 April 2012. Abstract 1184.
24. Poordad F, Lawitz E, De Jesus E, et al. ABT-072 or ABT-333 combined with pegylated interferon/ribavirin after 3-day monotherapy in HCV genotype 1 (GT1)-infected treatment-naive subjects: 12-week sustained virologic response (SVR12). In: 47th EASL, Barcelona, 18-22 April 2012. Abstract 1206.
25. Lawitz E, Poordad F, Kowdley K, et al. 1. A 12-week interferon-free regimen of ABT-450/r, ABT-072, and ribavirin was well tolerated and achieved sustained virologic response in 91% treatment-naive HCV IL28B-CC genotype-1-infected subjects. In: 47th EASL, Barcelona, 18-22 April 2012. Abstract 13.
26. Poordad F, Lawitz E, Kowdley K, et al. 12-week interferon-free regimen of ABT-450/r + ABT-333 + ribavirin achieved SVR12 in more than 90% of treatment-naive HCV genotype-1-infected subjects and 47% of previous non-responders. In: 47th EASL, Barcelona, 18-22 April 2012. Abstract 21.
27. Suzuki F, Ikeda K, Toyota J, et al. Dual oral therapy with the NS5A inhibitor daclatasvir (BMS-790052) and NS3 protease inhibitor asunaprevir (BMS-650032) in HCV genotype 1b-infected null responders or ineligible/ intolerant to peginterferon. In: 47th EASL, Barcelona, 18-22 April 2012. Abstract 14.
28. Sulkowski M, Rodriguez-Torres M, Lawitz E, et al. High sustained virologic response rate in treatment-naive HCV genotype 1a and 1b patients treated for 12 weeks with an interferon-free all-oral quad regimen: interim results. In: 47th EASL, Barcelona, 18-22 April 2012. Abstract 1421.
29. Bronowicki J, Hezode C, Bergtsoon L, et al. 100% SVR in IL28B SNP rs12979860 C/C patients treated with 12 weeks of telaprevir, peginterferon and ribavirin in the PROVE2 trial. In: 47th EASL, Barcelona, 18-22 April 2012. Abstract 1094.
30. Vijgen L, Talloen W, Scholliers A, et al. Pre-treatment IP-10 levels and IL28B genotype in prediction of SVR in prior treatment-experienced genotype 1 HCV patients treated with telaprevir/peginterferon/ribavirin in the REALIZE study. In: 47th EASL, Barcelona, 18-22 April 2012. Abstract 1167.
31. Picchio G, De Meyer S, Dierynk I, et al. A comprehensive review of patterns of viral load decline in patients treated with telaprevir plus peginterferon and ribavirin. In: 47th EASL, Barcelona, 18-22 April 2012. Abstract 1150.
32. Pinson P, Trimoulet P, Papuchon J, et al. Dynamics of HCV quasiespecies during telaprevir treatment dissected using ultra-deep pyrosequencing: treatment failure in 100% of genotype 1a patients. In: 47th EASL, Barcelona, 18-22 April 2012. Abstract 56.
33. Jacobson I, Bartels D, Gritz L, et al. Futility rules in telaprevir combination therapy. In: 47th EASL, Barcelona, 18-22 April 2012. Abstract 55.
34. Labarga P, Barreiro P, da Silva A, et al. Comparison of high ribavirin induction versus standard ribavirin dosing, plus peginterferon-α for the treatment of chronic hepatitis C in HIV-infected patients: the PERICO trial. J Infect Dis 2012; 206:961-8.
35. Sulkowski M, Roberts S, Afdhal N, et al. Ribavirin dose modification in treatment-naive and previously treated patients who received telaprevir combination treatment: no impact on sustained virologic response in phase 3 studies. In: 47th EASL, Barcelona, 18-22 April 2012. Abstract 1162.
36. Poordad F, Lawitz E, Reddy K, et al. A randomized trial comparing ribavirin dose reduction versus erythropoietin for anemia management in previously untreated patients with chronic hepatitis C receiving boceprevir plus peginterferon/ribavirin. In: 47th EASL, Barcelona, 18-22 April 2012. Abstract 1419.
37. Soriano V, Zeuzem S, Zoulim F. Why are there different dynamics in the selection of drug resistance in HIV and hepatitis B and C viruses? J Antimicrob Chemother 2008; 62:1-4.
38. Jacobson I, Bartels D, Gritz L, et al. Futility rules in telaprevir combination treatment. In: 47th EASL, Barcelona, 18-22 April 2012. Abstract 55.
39. Soriano V, Vispo E, Poveda E, Labarga P, Barreiro P. Treatment failure with new hepatitis C drugs. Expert Opin Pharmacother 2012; 13:313-23.
40. Kieffer T, Kwong A, Picchio G. Viral resistance to specifically targeted antiviral therapies for hepatitis C (STAT-Cs). J Antimicrob Chemother. 2010; 65:202-12.
41. Rallón N, Pineda JA, Soriano V, et al. Differences in virological response to peginterferon-α plus ribavirin in HIV-positive patients coinfected with HCV subtypes 1a or 1b. J Acquir Immune Defic Syndr 2012; 60:117-23.
42. Vispo E, Rallon N, Labarga P, et al. Different impact of IL28B polymorphisms on response to peginterferon plus ribavirin in HIVpositive patients infected with HCV subtypes 1a or 1b. J Clin Virol 2012; 55:58-61.
43. Bartels D, Zhou Y, Zhang E, et al. Natural prevalence of HCV variants with decreased sensitivity to NS3-4A protease inhibitors in treatmentnaive subjects. J Infect Dis 2008; 198:800-7.
44. Kuntzen T, Timm J, Berical A, et al. Naturally occurring dominant resistance mutations to HCV protease and polymerase inhibitors in treatment-naive patients. Hepatology 2008; 48:1769-78.
45. Plaza Z, Soriano V, Gonzalez MM, et al. Impact of antiretroviral therapy on the variability of the HCV NS5B polymerase in HIV/HCV co-infected patients. J Antimicrob Chemother 2011; 66:2838-42.
46. Bae A, Sun S, Qi X, et al. Susceptibility of treatment-naive hepatitis C virus (HCV) clinical isolates to HCV protease inhibitors. Antimicrob Agents Chemother 2010; 54:5288-97.
47. Treviño A, de Mendoza C, Parra P, et al. Natural polymorphisms associated with resistance to new antivirals against HCV in newly diagnosed HIV-HCV-coinfected patients. Antivir Ther 2011; 16:413-6.
48. Plaza Z, Soriano V, Vispo E, et al. Prevalence of natural polymorphisms at the HCV NS5A gene associated with resistance to daclatasvir, an NS5A inhibitor. Antivir Ther 2012; 17:921-6.
49. Lenz O, Fevery B, Vijgen L, et al. TMC-435 in patients infected with HCV genotype 1 who have failed previous pegylated interferon/ribavirin treatment: virological analyses of the ASPIRE trial. In: 47th EASL, Barcelona, 18-22 April 2012. Abstract 9.
50. Fabrycki J, Patel D, Yang G, et al. Characterization of HCV NS3 protease variants from patients enrolled in a 28-day phase 2a trial of ACH-1625 daily dosing plus pegIFN-alpha 2a/RBV. In: 47th EASL, Barcelona, 18-22 April 2012. Abstract 1182.
51. Drusano G, Preston S. A 48-week duration of therapy with pegylated interferon alpha 2b plus ribavirin may be too short to maximize longterm response among patients infected with genotype 1 hepatitis C virus. J Infect Dis 2004; 189:964-70.
52. Florian J, Chen J, Jadav P, et al. Consideration of new endpoints for regulatory approval and dose selection of hepatitis C therapies. In: 62nd AASLD, San Francisco, CA, 4-8 November 2011. Abstract LB-28.
53. Zeuzem S, Soriano V, Asselah T, et al. SVR4 and SVR12 with an interferon-free regimen of BI-201335 and BI-207127 +/-ribavirin, in treatment-naive patients with chronic genotype-1 HCV infection: Interim results of SOUND-C2. In: 47th EASL, Barcelona, 18-22 April 2012. Abstract 21.
54. Luo D, Zeuzem S, Jacobson I, et al. High concordance between SVR12 and SVR24 in patients receiving telaprevir plus peginterferon and ribavirin in three phase III clinical trials: ADVANCE, ILLUMINATE and REALIZE. In: 47th EASL, Barcelona, 18-22 April 2012. Abstract 1132.